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A Novel Non-Peptidic Agonist 
of the Ghrelin Receptor with 
Orexigenic Activity In vivo
Elena Pastor-Cavada1, Leticia M. Pardo2, Dalia Kandil3, Cristina Torres-Fuentes1, 
Sarah L. Clarke2, Hamdy Shaban3, Gerard P. McGlacken2 & Harriet Schellekens1,3
Loss of appetite in the medically ill and ageing populations is a major health problem and a significant 
symptom in cachexia syndromes, which is the loss of muscle and fat mass. Ghrelin is a gut-derived 
hormone which can stimulate appetite. Herein we describe a novel, simple, non-peptidic, 2-pyridone 
which acts as a selective agonist for the ghrelin receptor (GHS-R1a). The small 2-pyridone demonstrated 
clear agonistic activity in both transfected human cells and mouse hypothalamic cells with endogenous 
GHS-R1a receptor expression. In vivo tests with the hit compound showed significant increased food 
intake following peripheral administration, which highlights the potent orexigenic effect of this novel 
GHS-R1a receptor ligand.
Cachexia is a metabolic disorder or wasting syndrome, characterised by loss of weight, muscle atrophy, fatigue, 
weakness and significant loss of appetite, that affects millions of people worldwide, including as many as 80% of 
people with advanced cancer1. In fact, cachexia is seen in the late stages of almost every major chronic illness, 
affecting 16–42% of people with heart failure, 30% of those with chronic obstructive pulmonary disease and up to 
60% of people with kidney disease1,2. It typically involves extreme weight- and muscle-loss, makes routine activi-
ties difficult and increases the risk of infection. For many years it has been overlooked, as physicians and research-
ers have focused their attention on the primary illness. In 2006 a formal definition emerged, which included a 
loss of 5% or more of body weight over 12 months, and reduced muscle strength3. Now, scientists are increasingly 
viewing cachexia as a distinct, treatable condition which will undoubtedly lead to novel therapeutic options and 
improve health and mortality rates.
The regulation of food intake is coordinated in the hypothalamus in the brain. In particular, the arcuate 
nucleus of the hypothalamus (ARC) is critical for appetite regulation. Many factors are implicated in the hypotha-
lamic regulation of food intake. Among the peripheral peptides, ghrelin and leptin control the central orexigenic 
and anorexigenic effects respectively4,5. Other studies on crosstalk between the brain and muscle have assigned an 
important role to ghrelin in the mechanism of cachexia6.
Current treatment options to combat cancer cachexia are limited and mostly palliative. Thus novel strategies 
and new pharmacotherapies are urgently needed7. There is a growing interest in the study of ligands mimicking 
the appetite-enhancing effects of ghrelin to treat cachexia8. Ghrelin acts as an endogenous ligand for the growth 
hormone secretagogue receptor, or ghrelin receptor (GHS-R1a) and has a plethora of central and peripheral 
actions including the release of growth hormone from the pituitary gland9–14. Ghrelin also plays a key role in the 
regulation of energy balance by increasing appetite and decreasing energy consumption. This dual effect leads to 
a positive energy balance, increased food intake and weight gain. Because ghrelin needs parenteral administration 
and is a peptide with a 30 min half-life, its efficacy in patients is restricted15.
Apart from the natural agonist ghrelin, peptide and non-peptide GHS-R1a receptor agonists have been 
reported16–18. In fact, non-peptide mimetics of ghrelin are ideally poised for the development of successful, orally 
available administration, given the often inhibitory degradation of peptidic based structures19, yet reports of 
non-peptidic GHS-R1a receptor agonists are rare. However, anamorelin (which has a molecular weight of 546.7 g/mol 
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and contains two chiral centres) is currently under development by Helsinn Therapeutics for cancer cachexia and 
anorexia20.
2-Pyrones and their isosteres 2-pyridones are often termed ‘privileged structural motifs’, due to their 
wide-ranging pharmaceutic properties. In fact many of the key focus-areas of biology have been targeted by 
2-pyrone and 2-pyridone containing motifs21–23. However as far as we are aware, no report exists of the effect of 
2-pyrones or 2-pyridones on GHS-R1a receptor signaling. Thus as part of a wider screening program we sought 
to test these compounds for GHS-R1a receptor activity.
Results and Discussion
We initially designed a suite of 2-pyrones and 2-pyridones ranging from simple, commercially available frame-
works to novel more decorated structures (Fig. 1).
An initial screen of GHS-R1a receptor activation using intracellular calcium mobilisation, which is a measure 
of downstream GHS-R1a receptor signaling and activation12,24, was carried out in Hek-GHS-R1a-EGFP cells 
(human embryonic kidney cells) transfected to express the ghrelin receptor with an enhanced green fluorescent 
protein tag (EGFP) (Fig. 2). In Phase 1, simple 2-pyrones and 2-pyridones 1–3 were tested. Two out of the three 
showed modest GHS-R1a receptor activity. Modification of the C-3 position (4–8) dramatically improved the 
response in the case of pyridone 8. The introduction of a –CF3 group can significantly alter lipophilicity, mem-
brane permeability and oxidative metabolism25–29. Indeed incorporation of the –CF3 group gave dramatically 
improved activity. Finally, further modification at the N-substituent did not improve calcium influx (9–10). Thus, 
we chose compound 8 for more specific in vitro and in vivo tests.
Firstly, scale-up (4–5 g) of novel pyridone 8 was achieved via a simple 4 step route, employing a very cheap 
starting material 4-hydroxy-6-methyl-2-pyrone, 11 (Fig. 3). Refluxing this compound in N-methylamine gave the 
Figure 1. Synthesised 2-pyrones and pyridones. 
Figure 2. The synthetic small molecules differently affect calcium influx in Hek-GHS-R1a-EGFP cells 
compared to ghrelin (for details, see SI). 
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4-hydroxy substituted pyridone 12 in 55% yield, which can be transformed into the methoxy derivative 13 in 61% 
yield, and subsequently iodinated selectively at the C-3 position to give 14 in 36% yield.
Methyl 2,2-difluoro-2-(fluorosulfonyl) acetate (MFSDA) was used as the reagent for the trifluoromethylation 
of pyridone 14 to give novel pyridone 830,31. Before returning to in depth biological studies, the prepared pyridone 
8 was deemed not toxic in the two cell lines tested: Hek293a-GHS-R1a and mHypoE-N38 using the resazurin 
toxicity assay (for details, see SI, Figure S1).
In our next set of studies, pyridone 8 was directly compared to the endogenous GHS-R1a receptor agonist, 
ghrelin and the non-peptide agonist, MK-0677, in the calcium mobilisation assay using Hek-GHS-R1a-EGFP 
cells (for details, see SI, Figure S2). The hit compound stimulated an intracellular calcium influx, in vitro, on cells 
expressing the GHS-R1a receptor, in a dose dependent manner, with an efficacy of 100% and EC50 of 3.1 μM. The 
pyridone 8 EC50 was 35-fold lower compared to endogenous GHS-R1a receptor ligands, ghrelin (EC50 88 nM) and 
443-fold lower compared to the EC50 for MK-0677 (EC50 7 nM), a non-peptide GHS-R1a receptor agonist (for 
details, see SI, Figure S2). The EC50s obtained here for ghrelin and MK-0677 are equal to those previously reported 
by our laboratory as well as others32–35. In contrast, no calcium influx was observed in wild-type Hek cells, show-
ing selectivity for the GHS-R1a receptor. This was further supported by the lack of activity in cells expressing an 
unrelated serotonin 2C (5-HT2C) receptor (for details, see Supporting Information, SI, Figure S3). In addition, 
pyridone 8-mediated intracellular calcium mobilisation was enhanced in response to GHS-R1a receptor sensiti-
sation, following pre-treatment with the inverse agonist peptide, [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance 
P (SP-analog) (see SI, Fig. S4A). Inverse agonists, like SP-analog have been shown to decrease the high GHS-R1a 
constitutive activity leading to an increase of GHS-R1a receptor availability on the membrane. The SP-analog 
mediated attenuation of the ligand-independent constitutive activity of the GHS-R1a receptor, subsequently leads 
to enhanced agonist-mediated calcium signaling36. Pyridone 8 exposure, following SP-analog pre-treatment, was 
shown to significantly enhance the GHS-R1a receptor mediated calcium influx at 10 μM (p < 0.001) showing a 
greater calcium increase than ghrelin control exposure (for details, see SI, Fig. S4A). In addition, pre-treatment 
with the specific GHS-R1a receptor antagonist, JMV2959, followed by pyridone 8 exposure significantly reduced 
GHS-R1a receptor mediated calcium influx at 10 μm ( p ≤ 0.001) (see SI, Fig. 4B).
The effect of pyridone 8 on GHS-R1a receptor internalisation into endosomes (a characteristic of receptor 
desensitisation37) was then analysed. Both desensitisation and internalisation processes provide essential phys-
iological “feedback” mechanisms that protect against both acute and chronic overstimulation of receptors38. 
Internalisation and trafficking of the GHS-R1a-EGFP receptor was monitored following analysis of 
EGFP-mediated fluorescence intensity within the cell cytosol (Fig. 4). While the full agonist ghrelin led to a sig-
nificantly increased GHS-R1a-EGFP receptor internalisation, pyridone 8 exposure did not significantly change 
receptor trafficking. This suggests a functional selectivity of the pyridone 8 extract towards activation of the 
calcium signaling, without subsequent GHS-R1a receptor internalisation and desensitisation. In contrast, treat-
ment with the inverse agonist SP-analog did show a significantly decreased EGFP fluorescence intensity within 
the cytosol, due to blockade of ligand-independent constitutive receptor signaling and consequent increased 
membrane receptor expression. In any case, this result is informative and indeed suggests that pyridone 8 might 
ultimately allow for prolonged ghrelineric signaling.
Next, the effect of hit compound 8 on GHS-R1a-receptor mediated intracellular calcium mobilisation using 
confocal imaging was investigated. We focused especially on a hypothalamic neuronal cell line model of an 
embryonic mouse, the hypothalamus cell line-N38 (mHypoE-N38). It possesses endogenous levels of GHS-R1a 
Figure 3. Synthesis of pyridone 8. 
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receptor expression (see SI, Figure S5), and would therefore represent a physiologically relevant model to analyse 
the effects of the 2-pyridone, even predicting its ability to modify hypothalamic neurons in vivo. When pyridone 8 
was added, the normalised fluorescence intensity was significantly increased compared to baseline and the positive 
control, MK-0677, a known agonist of the GHS-R1a receptor39 (Fig. 5 and for a live imaging videoclip see the SI), 
indicating the potential of pyridone 8 as a novel agonist for the GHS-R1a receptor. Thus, we conclude that 
Figure 4. Pyridone 8 does not affect internalisation of the GSH-R1a receptor. Representative images are 
depicted following different treatments: untreated control (assay buffer), ghrelin (1 μM), [D-Arg1, D-Phe5, 
D-Trp7,9, Leu11]-substance P (SP-analog) (0.1 μM) and pyridone 8 (10 μM). Graph represents the mean ± SEM 
of quantified fluorescence intensity (15 pictures per treatment) of perinuclear GHS-R1a-EGFP receptor from a 
representative experiment (for details, see SI).
www.nature.com/scientificreports/
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pyridone 8 interacts with the GHS-R1a receptor, as elicited by increased intracellular calcium influx, measured 
using calcium mobilisation assay and confocal calcium imaging, and therefore acts as full GHS-R1a receptor 
agonist in vitro, without immediate GHS-R1a receptor internalisation and desensitisation. Finally, the biological 
activity of pyridone 8 was assessed in vivo via cumulative food intake measurements in male C57BL/6J mice. 
A significant acute increase in food intake was observed following intraperitoneal administration of pyridone 
8 in ad libitum fed mice (Fig. 6 and SI, S6). The endogenous ligand of the GHS-R1a receptor, ghrelin, was used 
as a reference compound and demonstrated increased food intake, as expected, mainly in the immediate phase 
after administration. It will be interesting to investigate if the prolonged food intake of pyridone 8 compared to 
ghrelin is related to an increased GHS-R1a receptor availability, since internalisation and subsequent GHS-R1a 
receptor desensitisation do not occur following pyridone 8 exposure. In addition, pharmacokinetics and bio-
availability of the novel pyridone 8 remain to be investigated. Together, the data confirm that the pyridone 8 acts 
as a potent GHS-R1a receptor agonist in vitro and in vivo. The in vivo activity of pyridone 8 is certainly worthy of 
further investigation. This is especially significant given that the GHS-R1a receptor agonists GHRP-6, L-692,429, 
L-692,585, and MK-0677 have been investigated for growth hormone release and c-fos expression in the hypo-
thalamus40, but effects on food intake have not been reported. In fact, we are aware of no other studies reporting 
non-peptide GHS-Ra receptor agonists with acute orexigenic effects (i.e. within first 2 hours of administration), 
apart for the novel pyridone 8, which we demonstrate here to modify food intake in vivo at two hours after admin-
istration and up to 6 hours. Moreover, the observed long-lasting effect of the orexigenic effect in mice (i.e. up to 
6 hours), following intraperitoneal injection of the 2-pyridone, is promising for the development of treatments 
for eating and metabolic disorders in humans. This is in sharp contrast to the native peptide ghrelin, which has an 
Figure 5. Pyridone 8 activates endogenous GHS-R1a receptor in hypopthalamic neurons. Pyridone 8 and 
MK-0677 interacting with GHS-R1a receptors in transfected human embryonic kidney (Hek293a) cells (A) 
and embryonic mouse hypothalamic cell line-N38 (B) by cell calcium imaging using confocal microscopy (for 
visualisation, see supplementary videos in SI).
Figure 6. Pyridone 8 increases cumulative food intake in vivo compared to vehicle. The GHS-R1a receptor 
ligand, ghrelin, is used as an orexigenic reference compound (for further details, see SI).
www.nature.com/scientificreports/
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initial orexigenic effect, following acute peritoneal administration, which tends to tapers off (relative to vehicle) 
after 2 hours41 (and SI, Figure S6), most likely due to its short half-life, and thus restricted efficacy in patients.
In summary, we describe a novel, small, non-peptidic 2-pyridone which acts as a potent GHS-R1a receptor 
agonist in vitro, which translates to an orexigenic effect in vivo. In the absence of any FDA approved treatment, 
the lead compound shows significant potential for use in the treatment of cachexia. Future development will pro-
gress in two ways: 1) Structural optimisation (installation of groups at the C3 position of pyrones and pyridones 
is difficult42–45 and will require the development of new chemistry) and, 2) further selectivity studies (beyond 
5HT-2c) to confirm GHS-R1a receptor specificity. However, a very promising molecular template has emerged 
and the fact that such a simple molecule demonstrates potent ghrelin receptor agonist activity (in vitro & in vivo), 
with promising selectivity is remarkable.
Material and Methods
Synthesis and Characterisation of compounds 1–10. General information. Melting point determi-
nations were performed by the open capillary method and are reported uncorrected. IR spectra were recorded on 
Perkin-Elmer FT-IR Paragon 1000 spectrophotometer. Liquid samples were examined as thin films interspersed 
on NaCl plates. Solid samples were dispersed in KBr and recorded as pressed discs. The intensity of peaks were 
expressed as strong (s), medium (m) and weak (w) and broad (b). 1H, 13C and 19F NMR spectra were recorded 
at 25 °C in CDCl3 at 300, 75 and 282 MHz spectrometer unless otherwise specified, with TMS as the internal 
standard. Chemical shifts (1H, 13C and 19F) were expressed as parts per million (ppm) positive shift being down-
field from TMS; coupling constants (J) are expressed in Hertz (Hz). High-resolution mass spectra (HRMS) were 
obtained on a TOF MS instrument with ESI source. Literature citations are provided for known compounds 
and representative characterisation data. Analytical thin layer chromatography (TLC) was performed on sil-
ica gel 60 F254 aluminum plates (Merck). TLC plates were visualized by exposure to short wave ultraviolet light 
(254 nm, 366 nm). Column chromatography was carried out using 60 Å (35–70 mm) silica. The Microanalysis 
Laboratory, National University of Ireland, Cork, performed elemental analysis using a Perkin-Elmer 240 and 
Exeter Analytical CE440 elemental analysers.
4-Methoxy-6-methyl-2H-pyran-2-one, 1
   
Compound 1 was prepared according to a known procedure and spectral characteristics 
were consistent with previously reported data46.
4-Hydroxy-1,6-dimethylpyridin-2(1H)-one, 2
   
Compound 2 was prepared according to a known procedure and spectral characteristics 
were consistent with previously reported data47.
4-Methoxy-1,6-dimethylpyridin-2(1H)-one, 3
   
Compound 3 was prepared according to a known procedure and spectral characteristics 
were consistent with previously reported data48.
4-Methoxy-6-methyl-3-(trifluoromethyl)-2H-pyran-2-one, 4
  
 Compound 4 was prepared according to a known procedure and spectral characteristics 
were consistent with previously reported data31.
3-Chloro-4-methoxy-1,6-dimethylpyridin-2(1H)-one, 5
  To a stirred solution of 4-methoxy-1,6-dimethylpyridin-2(1H)-one, 3, (0.500 g, 
3.3 mmol) in acetonitrile (10 mL) was added N-chlorosuccinimide (0.880 g, 6.6 mmol). 
The reaction vessel was covered in aluminium foil and resulting mixture allowed to stir 
at reflux overnight. The solvent was concentrated in vacuo, the resulting solid dissolved 
in CH2Cl2 (20 mL) and washed with 5% aqueous sodium thiosulfate (2 × 25 mL), water 
(25 mL) and brine (25 mL). The organic layer was dried over MgSO4 and concentrated in 
vacuo to yield crude product, which was purified by silica column chromatography to 
yield compound 5 as a pale yellow solid (0.316 g, 51% yield). m.p. 168–170 °C. IR (KBr) 
νmax: 1649 (amide C=O stretch, s), 1589 (aromatic C=C stretch, s), 1350 (ester C-O 
www.nature.com/scientificreports/
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stretch, s) cm−1; 1H NMR (300 MHz, CDCl3): δ 2.38 (3H, s, CH3), 3.56 (3H, s, NCH3), 3.92 (3H, s, OCH3), 5.96 
(1H, s, CH) ppm; 13C NMR (75.5 MHz, CDCl3): δ 21.4 (CH3), 32.0 (NCH3), 56.4 (OCH3), 105.4 (C-Cl), 94.8 
(CH), 145.1 (CH3CCH), 160.8 (C=O), 161.7 (COCH3), ppm; HRMS (ESI) m/z calcd for C8H11NO2Cl 
[(M + H)+]: 188.0478, found 188.0470.
3-Iodo-4-methoxy-1,6-dimethylpyridin-2(1H)-one, 6
  To a stirred solution of 4-methoxy-1,6-dimethylpyridin-2(1H)-one, 3, (0.362 g, 
2.36 mmol) in acetonitrile (15 mL) was added N-iodosuccinimide (1.603 g, 4.73 mmol). The 
reaction vessel was covered in aluminium foil and allowed stir at reflux overnight. On com-
pletion, the solvent was concentrated in vacuo, the resulting orange solid dissolved in CH2Cl2 
(20 mL) and washed with 5% aq. sodium thiosulfate (3 × 25 mL). The organic layer was dried 
over MgSO4 and concentrated in vacuo to yield crude product which was purified by silica 
column chromatography eluting with 70:30 hexane:ethyl acetate to yield compound 6 as a 
yellow solid (0.238 g, 36%). m.p. 191–193 °C. IR (KBr) νmax: 1628 (amide C=O stretch, s), 1585 (aromatic C=C 
stretch, s), 1342 (ester C-O stretch, s) cm−1; 1H NMR (300 MHz, CDCl3): δ 2.35 (3H, s, CH3), 3.57 (3H, s, NCH3), 
3.88 (3H, s, OCH3), 5.86 (1H, s, CH) ppm; 13C NMR (75.5 MHz, CDCl3): δ 21.4 (CH3), 32.5 (NCH3), 56.6 (OCH3), 
71.8 (C-I), 94.7 (CH), 147.6 (CH3CCH), 162.0 (C=O), 166.5 (COCH3), ppm; HRMS (ESI) m/z calcd for 
C8H11NO2I [(M + H)+]: 279.9835, found 279.9827.
3-Bromo-4-methoxy-1,6-dimethylpyridin-2(1H)-one, 7
To a stirred solution of 4-methoxy-1,6-dimethylpyridin-2(1H)-one, 3, (0.500 g, 3.3 mmol) in 
acetonitrile (10 mL) was added N-bromosuccinimide (1.180 g, 6.6 mmol). The reaction ves-
sel was covered in aluminium foil and resulting mixture allowed to stir at reflux overnight. 
The solvent was concentrated in vacuo, the resulting solid dissolved in CH2Cl2 (20 mL) and 
washed with 5% aqueous sodium thiosulfate (2 × 25 mL), water (25 mL) and brine (25 mL). 
The organic layer was dried over MgSO4 and concentrated in vacuo to yield crude product, 
which was purified by silica column chromatography to yield compound 7 as a pale yellow 
solid (0.345 g, 45% yield). m.p. 170–172 °C. IR (KBr) νmax: 1651 (amide C=O stretch, s), 1593 (aromatic C=C 
stretch, s), 1346 (ester C-O stretch, s) cm−1; 1H NMR (300 MHz, CDCl3): δ 2.35 (3H, s, CH3), 3.54 (3H, s, NCH3), 
3.89 (3H, s, OCH3), 5.91 (1H, s, CH) ppm; 13C NMR (75.5 MHz, CDCl3): δ 21.4 (CH3), 32.2 (NCH3), 56.4 (OCH3), 
94.8 (CH), 95.7 (C-Br),146.2 (CH3CCH), 163.2 (C=O), 177.2 (COCH3), ppm; HRMS (ESI) m/z calcd for 
C8H11NO2Br [(M + H)+]: 231.9973, found 231.9976.
4-Methoxy-1,6-dimethyl-3-(trifluoromethyl)pyridin-2(1H)-one, 8
 To a stirred solution of 3-iodo4-methoxy-1,6-dimethylpyridin-2(1H)-one, 6, (0.235 g, 
0.84 mmol) and copper(I) iodide (0.192 g, 1.01 mmol) in DMF (4 mL) was added methyl 2,2- 
difluoro-2-(fluorosulfonyl)acetate (0.13 mL, 1.01 mmol). The reaction mixture was allowed 
stir at 70 °C for 7 h. On completion, the reaction was cooled to room temperature, diluted 
with diethyl ether (20 mL) and filtered. The solution was poured into water (20 mL), extracted 
with diethyl ether (4 × 20 mL) and the combined organic extracts washed with water 
(3 × 5 mL). The organic layer was dried over MgSO4 and concentrated in vacuo to yield crude 
product which was purified using silica column chromatography eluting with 70:30 hexane:ethyl acetate to yield 
8 as a white solid (0.114 g, 61%). m.p. 136–138 °C. IR (KBr) νmax: 1651 (amide C=O stretch, s), 1598, 1563 (aro-
matic C=C stretch, s), 1130 (ester C-O stretch, s) cm−1; 1H NMR (300 MHz, CDCl3): δ 2.40 (3H, s, CH3), 3.47 
(3H, s, NCH3), 3.89 (3H, s, OCH3), 5.92 (1H, s, CH) ppm; 13C NMR (75 MHz, CDCl3): δ 21.8 (CH3), 30.9 (NCH3), 
56.3 (OCH3), 94.1 (CH), 99.9 (q, 2JC-F = 29.2 Hz, CCF3), 124.0 (q, 1JC-F = 272.8 Hz, CF3), 151.4 (CH3CCH), 
160.7 (C = O), 166.4 (COCH3) ppm19; F NMR (282 MHz, CDCl3): δ −57.4 (CF3) ppm; HRMS (ESI) m/z calcd for 
C9H11F3NO2 [(M + H)+]: 222.0742, found 222.0736; Anal. calcd for C9H10F3NO2: C, 48.87; H, 4.56; N, 6.33%. 
Found: C, 49.09; H, 4.43; N, 6.19%.
4-Methoxy-6-methyl-1-phenyl-3-(trifluoromethyl)pyridin-2(1H)-one, 9
To a round bottomed flask containing 4-hydroxy-6-methyl-1-phenylpyridin-2(1H)-one49 
(0.776 g, 3.86 mmol) and K2CO3 (0.640 g, 4.63 mmol) was added trimethylphosphate 
(0.93 mL, 8.01 mmol) and the resulting reaction mixture stirred at reflux overnight. On com-
pletion, the reaction was washed with water (15 mL) and extracted with ethyl acetate 
(3 × 25 mL). The combined organic extracts were dried over MgSO4 and concentrated in 
vacuo to yield crude product as an orange oil which was purified by silica column chroma-
tography eluting with ethyl acetate to yield 4-methoxy-6-methyl-1-phenylpyridin-
2(1H)-one a pale yellow solid (0.578 g, 70%). m.p. 162–163 °C. IR (KBr) νmax: 2968 (alkyl C-H stretch, m), 1650 
(amide C=O stretch, s), 1597, 1562 (aromatic C=C stretch, s), 1243 (C-O stretch, m) cm−1; 1H NMR (300 MHz, 
CDCl3): δ 1.85 (3H, s, CH3), 3.73 (3H, s, OCH3), 5.81 (1H, s, CH3CCH), 5.85 (1H, d, J = 2.5 Hz, CHC=O), 7.14 
(2H, d, J = 7.4 Hz, 2 × CH arom.), 7.36–7.48 (3H, m, 3 × CH arom.) ppm; 13C NMR (75.5 MHz, CDCl3): δ 21.5 
(CH3), 55.4 (OCH3), 95.0 (CHC=O), 100.8 (CH3CCH), 128.3, 128.7, 129.7 (5 × CH arom.), 138.7 (NC), 146.0 
(CH3CCH), 165.5 (C=O), 167.9 (COCH3) ppm; HRMS (ESI) m/z calcd for C13H14NO2 [(M + H)+]: 216.1025, 
found 216.1018; Anal. calcd for C12H11NO2: C, 71.63; H, 5.51; N, 6.96%. Found: C, 71.64; H, 5.71; N, 6.77%. To a 
stirred solution of 4-methoxy-6-methyl-1-phenylpyridin-2(1H)-one (0.578 g, 2.69 mmol) in acetonitrile (25 mL) 
was added N-iodosuccinimide (1.208 g, 5.37 mmol). The reaction vessel was covered in aluminium foil and 
allowed stir at reflux for 12 h. On completion, the solvent was concentrated in vacuo, the resulting brown solid 
dissolved in CH2Cl2 (20 mL) and washed with 5% aq. sodium thiosulfate (3 × 20 mL). The organic layer was dried 
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over MgSO4 and concentrated in vacuo to give crude product which was purified using silica column chromatog-
raphy eluting with 50:50 hexane:ethyl acetate to yield 3-iodo-4-methoxy-6-methyl-1-phenylpyridin-2(1H)-one 
as a pale brown solid (0.768 g, 84%). m.p. 222–224 °C. IR (KBr) νmax: 1639 (amide C=O stretch, s), 1590, 1518 
(aromatic C=C stretch, s), 1226 (ether C-O stretch, s) cm−1; 1H NMR (300 MHz, CDCl3): δ 2.01 (3H, s, CH3), 3.97 
(3H, s, OCH3), 5.99 (1H, s, CH), 7.16 (2H, d, J = 7.6 Hz, 2 × CH arom.), 7.41–7.52 (3H, m, 3 × CH arom.) ppm; 
13C NMR (75.5 MHz, CDCl3): δ 22.0 (CH3), 56.8 (OCH3), 72.2 (C-I), 94.7 (CH), 127.9, 128.9, 129.7 (5 × CH 
arom.), 138.9 (NC), 147.6 (CH3CCH), 162.2 (C=O), 167.2 (COCH3) ppm; HRMS (ESI) m/z calcd for C13H13O2NI 
[(M + H)+]: 341.9991, found 341.9984; Anal. calcd for C13H12O2NI: C, 45.77; H, 3.55; N, 4.11%. Found: C, 45.81; 
H, 3.57; N, 3.77%. To a stirred solution of 3-iodo-4-methoxy-6-methyl-1-phenylpyridin-2(1H)-one (0.356 g, 
1.04 mmol) and copper(I) iodide (0.239 g, 1.25 mmol) in DMF (4 mL) was added methyl 2,2-difluoro-2-(fluoro-
sulfonyl)acetate (0.26 mL, 1.04 mmol). The reaction mixture was allowed stir at 70 °C for 24 h. On completion, the 
reaction was cooled to room temperature, diluted with diethyl ether (20 mL) and filtered. The solution was poured 
into water (20 mL), extracted with diethyl ether (4 × 20 mL) and the combined organic extracts washed with water 
(3 × 5 mL). The organic layer was dried over MgSO4 and concentrated in vacuo to yield crude product as a white 
solid which was purified by silica column chromatography eluting with 80:20 hexane:ethyl acetate to yield 
4-methoxy-6-methyl-1-phenyl-3-(trifluoromethyl)pyridin-2(1H)-one, 9, as a pale yellow solid (0.086 g, 29%). 
m.p. 205–207 °C. IR (KBr) νmax: 1658 (amide C=O stretch, s), 1551 (aromatic C=C stretch, s), 1392 (ether CO 
stretch, s) cm−1; 1H NMR (300 MHz, CDCl3): δ 2.03 (3H, s, CH3), 3.96 (3H, s, OCH3), 6.01 (1H, s, CH), 7.16–7.18 
(2H, m, 2 × CH arom.), 7.44–7.53 (3H, m, 3 × CH arom.) ppm; 13C NMR (75 MHz, CDCl3): δ 22.4 (CH3), 56.5 
(OCH3), 94.1 (CH), 100.5 (q, 2JC-F = 28.3 Hz, CCF3), 123.8 (q, 1JC-F = 273.0 Hz, CF3), 128.0, 129.1, 129.8 (5 × CH 
arom.), 137.8 (NC), 151.5 (CH3CCH), 160.9 (C=O), 167.3 (COCH3) ppm; 19F NMR (282 MHz, CDCl3): δ −57.2 
(CF3) ppm; HRMS (ESI) m/z calcd for C14H13NO2F3 [(M + H)+]: 284.0898, found 284.0893.
1-Benzyl-4-methoxy-6-methyl-3-(trifluoromethyl)pyridin-2(1H)-one, 10
Compound 10 was prepared according to a known procedure and spectral characteristics 
were consistent with previously reported data31.
Biological Tests: Materials and Methods. Compounds. The pyridone 8 was dissolved in assay buffer 
(1x Hanks balanced salt solution, HBSS, containing 20 mM HEPES) at 10 μM containing 0.3% DMSO and diluted 
further to desired concentrations. The GHS-R1a receptor agonists ghrelin (SP-GHRL, Innovagen) and MK-0677 
(#5272, Tocris), JMV2959 (JMV) (#345888, Calbiochem), as well as the inverse agonist [D-Arg1, D- 102 Phe5, D 
Trp7,9, Leu11]Substance P (SP-analog) (#1946, Tocris) were prepared as stock solution at several concentrations 
in assay buffer.
Cell culture. Human embryonic kidney cells (Hek293a) (Invitrogen) were maintained in culture in high glucose 
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) containing 10% heat inactivated fetal bovine serum 
(FBS) (Sigma-Aldrich) and 1% non-essential amino acids (NEAA) (Gibco) at culture conditions (37 °C and 5% 
CO2 in a humidified atmosphere). Hek293a cells were stably transfected with a plasmid construct expressing the 
human GHS-R1a receptor (Genecopeia, X0963; Accession code, U60179.1) as previously described35 and cul-
tured in complete DMEM media, containing 300 ng/μl G418 (Calbiochem) as maintenance antibiotic.
Embryonic mouse hypothalamus cell line N38 (mHypoE-N38) (Cederlane Laboratories) were maintained 
in culture in high glucose Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) containing 10% heat inac-
tivated fetal bovine serum (FBS) (Sigma-Aldrich) at culture conditions (37 °C and 5% CO2 in a humidified 
atmosphere).
Cells were grown to a confluence of >85% and subsequently split to a lower density for continued culturing.
Resazurin assay. Cytotoxicity of pyridone was determined using the resazurin assay (R&D systems, Inc.) 
according to manufacturer’s instructions. Resazurin is a blue non-toxic, water soluble, redox-sensitive dye that 
undergoes a colour change following reduction by viable cells. Absorbance of the colour change is measured at 
570 nm. Hek293a-GHS-R1a and mHypoE-N38 cells were seeded in a 96-well microtiter plate at 2.8 * 105 cells/ml 
(2.8 * 104 cells/well) and maintained for 48 h at culture conditions. For the last 24 h of this time period, media was 
replaced with serum free DMEM media containing 1% NEAA to mimic calcium mobilization assay conditions. 
Pyridone 8 was dissolved in saline at 10 μM containing 0.3% DMSO (Sigma-Aldrich). Then, it was centrifuged 
for 5 min at 2000 rpm and the supernatant was used to analyse its cytotoxicity. Cells were exposed for 4 h to this 
pyridone comprising 10% resazurin dye. Cell viability was calculated as percentage of control (cells in 1x Hanks 
balanced salt solution, HBSS) (Gibco), supplemented with 20 mM HEPES (Sigma-Aldrich). Values above 90% 
were deemed viable and hence compounds used for cell exposure not cytotoxic.
Calcium mobilisation assay. G-protein coupled receptor-mediated changes in intracellular calcium (Ca2+) were 
determined using a Flex station II multiplate fluorometer (Molecular Devices). Calcium mobilisation assays were 
performed according to the manufacturer’s instructions and as previously described34,35. Briefly, stably transfected 
Hek293a cells were seeded in black wall, clear bottom 96-well microtiter plates at a density of 2.8 * 105 cells/ml 
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(2.8 * 104 cells/well) and maintained at culture conditions overnight. At cell density of 80–90%, growth media 
was replaced by serum free DMEM media containing 1% NEAA for a further incubation at culture conditions 
overnight. After removal of the serum free DMEM media, cells were incubated for 90 min with 25 μl of assay 
buffer (1x Hanks balanced salt solution, HBSS, containing 20 mM HEPES) and 25 μl of 1x Ca4 dye (Molecular 
Devices). While it has been determined that 2.5% DMSO is not toxic to cells34, the DMSO concentration 
exposed directly on the cells was no higher than 0.33% in this assay. Fluorescent readings were taken for a total 
of 80 seconds at 37 °C in flex mode with excitation wavelength of 485 nm and emission wavelength of 525 nm. 
Addition of ghrelin or a serial dilution of the test compound 8 (25 μl/well) was performed by the Flexstation II 
after 16 sec during continuous fluorescent measurements for a total of 80 secs. The relative increase in intracellular 
calcium [Ca2+] was calculated as the difference between maximum and baseline fluorescence (Vmax-Vmin) and 
depicted as percentage relative fluorescent units (RFU) normalized to maximum response (100% signal) obtained 
with 3.3% FBS, which gives a maximal calcium influx. Background fluorescence was obtained by cells in assay 
buffer alone and subtracted from RFUs. Exposure to pyridone 8 and endogenous ligand, ghrelin, following 
pretreatment to the inverse agonist [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P were also carried out. To 
this end, pretreatment was performed during the 90 min of calcium dye incubation. Responses are considered 
positive when calcium influx exceeds 20% compared to control. Data were analysed using GraphPad Prism 
software (PRISM 5.0; GraphPAD Software Inc., San Diego, CA, USA). Sigmoidal dose-response curves were 
constructed using nonlinear regression analysis with variable slope, excluding values resulting from obvious 
incorrect pipetting by the Flexstation II.
Receptor internalisation assay. The potential of compounds to internalise the GHS-R1a receptor expressed 
with a C-terminal enhanced green fluorescent protein (EGFP) tag was analysed using an internalisation assay. 
Hek-GHS-R1a-EGFP cells were seeded in a poly-L-lysine (Sigma-Aldrich) coated 96-well microtiter plate at 
3 * 104 cells per well and incubated for 48 h at culture conditions. For the last 16–24 h of this time period media 
was replaced with serum free DMEM media. Cells were treated with pyridone 8 solution at 10 μM containing 
0.3% DMSO for 1 h at 37 °C. The cells were fixed with 4% paraformaldehyde in phosphate buffer saline (PBS) 
for 20 min, washed three times with PBS. Ligand induced GHS-R1a-EGFP trafficking was imaged on the GE 
Healthcare IN Cell Analyser 1000 (GE Healthcare, Buckinghamshire, UK) in PBS. Ghrelin was used as posi-
tive control. In addition, treatment with the inverse agonist, [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P 
(SP-analog), which inhibits GHS-R1a receptor constitutive activity and enhances GHS-R1a receptor membrane 
expression, was also carried out. Receptor trafficking was quantified using the InCell Analyzer Developer Toolbox 
V1.6 software (GE Healthcare, Buckinghamshire, UK) and expressed as EGFP fluorescence intensity (I) in the 
cell cytoplasm. Briefly, a total of 15 pictures were analysed using the automated software across 3 independent 
images. Considering that the GHS-R1a-EGFP receptor accumulates in the perinuclear space after internalisation, 
a target segmentation based on the fluorescence intensity of perinuclear space was used. The average fluorescence 
intensity was expressed as the mean ± SEM. Data were analysed and depicted using GraphPad Prism software 
(PRISM 5.0; GraphPAD Software Inc.).
Confocal microscopy technique. HEK-GHS-R-1a-EGFP cells and mHypoE-N38 were seeded in poly-L-lysine 
coated 35 mm dishes plate (MatTek) at a density of 15 * 104 cells/ml and maintained for ~24 h at culture conditions 
(37 °C and 5% CO2 in a humidified atmosphere). After 24 hours in culture cells were incubated for 40 minutes at 
37 °C in a 4 uM solution of Fluo 4 AM (Molecular probes) for HEK-GHS-R-1a-EGFP cells and in a 8 uM solution 
of Fluo 4 AM for mHypoE-N38 cells. After removal of the dye, cells were washed twice with PBS and 2 ml of assay 
buffer (1x Hanks balanced salt solution, HBSS, containing 20 mM HEPES) were added to the cells which were 
stored in the dark at 37 °C until visualisation under microscope.
Each dish was mounted on the stage, under culture conditions (37 °C and 5% CO2 in a humidified atmos-
phere) for stable recording for longer period of time using laser scanning confocal fluorescent microscopy 
(FV 1000 Confocal System; Olympus). Fluorescence was visualised on an inverted microscope (CKX41; 
Olympus) setup with a sensitive XM10 camera (C-BUN-F-XM10-BUNDLE) with an infrared cut filter, mercury 
burner (USH-103OL), and fluorescence condenser (CKX-RFA; Olympus). Green Flourescence of tagged GFP 
protein was monitored with excitation wavelength of 485 nm and emission wavelength of 525 nm. The same con-
figuration was used to monitor calcium mobilisation signals. For image acquisition 500 usecond/pixel was used. 
Cells within a single field of view were imaged over 1 minute period in absence of compound (line base) with a 
10-s shuttered interval between each image. When each compound was added the field of view was imaged over a 
2 minutes period, with a 1-s shuttered interval between each image. Fluorescent intensity changes (from t 0) were 
measured and expressed as area under the curve and normalised against baseline.
Cumulative food intake. A total of 24 male C57BL/6J mice (Harlan laboratories), 8 weeks of age on date of 
arrival, were group housed in standard holding cages at the animal care facility of University College Cork. The 
holding room temperature (21 ± 1 °C) and humidity (55 ± 10%) were controlled under a 12 h light/dark cycle 
(lights on 7.00 AM, lights off 7.00 PM. Water and food (2018S Teklad Global 18% Protein Rodent Diet, Harlan lab-
oratories) were available ad libitum for the duration of the study unless otherwise stated. Mice underwent habitu-
ation to experimental conditions over three consecutive days prior to experimentation in which they were single 
housed for up to 4 hours following intraperitoneal injection of saline (0.9% NaCl). Following this cumulative food 
intake studies, with eight animals per group, were performed based on protocols described in previous studies41,50. 
Briefly, on the day of experimentation animals were single housed for 30 minutes without access to food or water. 
Following this, mice subsequently received intraperitoneal injections of vehicle (saline, 1% DMSO), ghrelin 
(200 nmol/kg) or pyridone 8 (10 mg/kg in 1% DMSO). The dose of ghrelin was based on previous studies50,51. 
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Dose of the unknown, pyridone 8, was based on similar experiments with small molecules52–55. After 20 minutes 
a pre- weighed chow food pellet was placed into the cage and was subsequently weighed at regular time intervals 
(30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 5 h and 6 h). At the end of the experiment the mice were placed back into their 
original group cages. Data were analysed using GraphPad Prism software (PRISM 5.0; GraphPAD Software Inc.). 
All experiments were approved by the Animal Experimentation Ethics Committee at University College Cork and 
were carried out in accordance with the relevant guidelines - 200 European Directive 2010/63/EU.
Statistical analysis. Statistical analysis was performed using SPSS software (IBM SPSS statistics 22). Normality 
of the data as well as homogeneity of variance were tested by Shapiro-Wilk test and Levene test respectively. For 
in vitro data analysis a one-way ANOVA followed by Bonferroni post hoc test (when comparing all groups against 
each other) or Dunnett test (when comparing against a control group) was performed if data was distributed 
normal and variance was homogenous for all groups. A non-parametric multiple comparisons Kruskal-Wallis 
test was performed if data was not normal, followed by, where appropriate, Mann-Whitney U tests for individual 
comparisons. Cumulative food intake was analysed using a general linear model of repeated measures, followed 
by a one-way ANOVA and multiple comparison tests (LSD post hoc) to analyse specific time points. Level of sig-
nificant in all analysis was α = 0.05 and all tests were two-tailed test. All graphs represent the mean ± SEM from 
N independent experiments (see figure legends for N details for each experiment). Statistical significances are 
subsequently depicted as follows: *indicating p ≤ 0.05, **indicating p ≤ 0.01 or ***indicating p ≤ 0.001.
Biological Tests: Results. Cytotoxicity assay for pyridone 8. The potential cytotoxicity of pyridone 8 solu-
tion was analysed to test its suitability for cell culture studies. This was assessed by the resazurin assay, which is 
a widely used method to analyse viability of bacteria and mammalian cells56. Viability of Hek cells (Figure S1A) 
and N-hypothalamus cells are depicted (Figure S1B), calculated as percentage of control (cells in assay buffer, 
HBSS/20 mM HEPES). Cells were exposed for 4 h to pyridone 8 solution at 10 uM concentration. No cytotoxic 
effects were observed (<4%), showing a cellular viability around 100% with respect to the control, which makes 
the pyridone 8 a safe, suitable compound for the cellular calcium mobilisation assay.
Screen of compounds 1–10 on calcium influx of GHS-R1a receptor on Hek-GHS-R1a-EGFP cells. Compound- 
mediated intracellular calcium mobilisation via the GHS-R1a receptor in Hek-GHS-R1a-EGFP cells was ana-
lysed (Fig. 2). Pyridones tested consisted of simple 2-pyrones and 2-pyridones (1–3), pyridones with modified 
C-3 position (4–8) and modification at the N-substituent (9–10). Pyridone 8 showed increased calcium influx 
versus other synthetic compounds and negative control (serotonin). Pyridone 8 was superior in GHS-R1a recep-
tor mediated calcium influx, also compared to the endogenous ligand ghrelin (p ≤ 0.001), and was selected for 
further in vitro and in vivo tests.
Specific GHS-R1a receptor in vitro activation by pyridone 8. GHS-R1a receptor modulation following pyridone 
8 exposure was analyzed in the calcium mobilisation assay and compared with the natural agonist ghrelin across 
cells not expressing the GHS-R1a receptor (wild-type Hek cells, Hek293A wt) and in cells expressing an unrelated 
G-protein receptor, the serotonin 2C (5-HT2C) receptor. No calcium influx was observed in wild-type Hek cells 
(Hek293A wt, not expressing the GHS-R1a receptor) when exposed to pyridone 8 and ghrelin (Figure S2). In 
addition, neither pyridone 8 nor the agonist ghrelin, were able to activate the 5-HT2C receptor, indicating speci-
ficity for the GHS-R1a receptor (Figure S2).
Exposure of Hek cells stably expressing the GHS-R1a receptor (Hek-GHS-R1a-EGFP) to a serial dilution of 
pyridone 8 demonstrated a GHS-R1a receptor-mediated calcium influx in a concentration dependent manner 
(Figure S3). Pyridone 8 activated the GHS-R1a receptor with an EC50 of ~2 uM and efficacy of 100%, behaving 
as a fullGHS-R1a receptor agonist.
The pyridone 8 mediated calcium mobilisation following pre-treatment with the GHS-R1a receptor specific 
inverse agonist peptide, [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P (SP-analog) was analysed (Figure S4a). 
Pyridone 8 exposure following SP-analog pre-treatment did significantly enhance the GHS-R1a receptor 
mediated calcium influx at 10 μM (p ≤ 0.001) showing a similar calcium increase compared to ghrelin control 
(333 nM) exposure following SP-analog preincubation. In addition, pre-treatment with the specific GHS-R1a 
receptor antagonist, JMV2959, followed by pyridone 8 exposure significantly reduced GHS-R1a receptor medi-
ated calcium influx at 10 μm ( p ≤ 0.001) (Figure S4b).
GHS-R1a receptor internalisation by pyridone 8. The GHS-R1a receptor has a high constitutive activity in the 
absence of ligand. Following ligand-mediated receptor activation a desensitisation process occurs in order to 
protect the cell against receptor overstimulation57. This process of desensitisation is a consequence of a com-
bination of the uncoupling of the receptor from heterotrimeric G proteins and its internalisation from mem-
brane to intracellular compartments into endosomes57. Then, the receptor is marked for degradation or recycling 
back to the membrane and is a hallmark of receptor activation38. Following exposure to agonists, like ghrelin, 
the GHS-R1a receptor also internalises after signaling, which desensitises the receptor and attenuates further 
GHS-R1a receptor signaling. Internalisation of the GHS-R1a receptor was investigated in Hek cells stably express-
ing the receptor as an EGFP-tagged fusion construct. GHS-R1a receptor trafficking could be monitored follow-
ing analysis of EGFP fluorescent translocation from the cellular membrane into endosomes within the cytosol 
(untreated, Fig. 4A). Clear internalisation of the GHS-R1a receptor could be observed after treatment with the 
endogenous agonist ghrelin at 1 μm (Fig. 4B). After treatment with the pyridone 8, no changes in GHS-R1a 
receptor internalisation compared to untreated cells was observed (Fig. 4D). In contrast, treatment with inverse 
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agonist SP-analog resulted in increased GHS-R1a-EGFP receptor translocation to the membrane with respect 
to untreated cells (Fig. 4C) and consequently a significant decreased EGFP fluorescence intensity in the cytosol 
(p ≤ 0.001) (Fig. 4E). In conclusion, pyridone 8 did not affect GHS-R1a-EGFP fluorescence translocation, which 
means that GHS-R1a receptor desensitization does not occur and the GHS-R1a receptor remains available on the 
membrane for continued signaling (Fig. 4E).
Pyridone 8 activity on HEK-GHS-R1a-EGFP cells and embryonic mouse N-hypothalamus cell line-N38 using con-
focal microscopy. Cell calcium imaging using confocal microscopy was carried out to know more about the 
pyridone 8 interacting with ghrelin receptors in HEK-GHS-R1a-EGFP cells and in the embryonic mouse hypo-
thalamus cell line-N38 (mHypoE-N38), which is an immortalised neuronal cell line with endogenous levels of 
GHS-R1a receptor expression. MK-0677 (a known agonist of ghrelin) was used as a positive control58–61.
Figure 5A shows a significant increase in the GHS-R1a receptor activation as measured by normalised fluo-
rescence intensity on Hek-293A-GHS-R1a-EGFP for both compounds (p ≤ 0.01 for MK-0677 and pyridone 8). 
Figure 5B shows a significant increase in calcium mobilisation in the mHypoE-N38 cell line for both compounds 
(p ≤ 0.001 for MK-0677 pyridone 8). Baseline shows normalised fluorescence in the absence of any compound. 
Finally, Fig. 5B also shows a significant enhanced response (p ≤ 0.001) of the pyridone 8 with respect to MK-0677 
in embryonic mouse hypothalamic immortalised neurons (mHypoE-N38).
Cumulative food intake. The effect of pyridone 8 on cumulative food intake was investigated in male C57BL/6J 
mice (n = 8 vehicle, n = 7 ghrelin and n = 8 pyridone 8) at the start of the light cycle (Fig. 6). Pyridone 8 (10 mg/kg 
in saline containing 1% DMSO), ghrelin (200 nmol/kg in saline containing 1% DMSO) or vehicle (saline, 1% 
DMSO) were administered to ad libitum fed mice via intraperitoneal (IP) injection 20 minutes before placement 
of pre weighed food pellets in the cages. Cumulative food intake was measured at regular time intervals over six 
hours. Repeated measures analysis revealed a clear significant effect of time F (7, 140) = 128.5; p < 0.000 and a 
significant interaction of treatment × time F (14, 140) = 3.518; p < 0.000 compared to vehicle (Fig. 6) with post 
hoc LSD analysis showing an overall significant effect of treatment X time of ghrelin and pyridone 8 (p = 0.023 
and p = 0.004 respectively). Post hoc LSD analysis of cumulative food intake showed an overall significant effect 
of acute exposure to 200 nmol/kg ghrelin treatment at individual time points 30 minutes to 2 hours. Specifically, 
ghrelin significantly increased food intake compared to vehicle and pyridone 8 at 30 minutes (p = 0.022 and 
p = 0.004, respectively, Figure S5A) and compared to vehicle at 1 h 30 min (p = 0.04, data not shown) and 2 hours 
after injection (p = 0.23 and 0.011 respectively, Figure S5B). Ghrelin’s orexigenic effect is known to be immediate 
and then taper off, as previously reported in our laboratory, as well as in other groups33,41,51. Post hoc LSD analysis 
of cumulative food intake showed an overall significant effect of exposure to 10 mg/kg pyridone 8 treatment at 
individual time points from 2 hours onwards. A significant higher cumulative food intake was observed with 
pyridone 8 compared to the vehicle control after 2 h following food placement until the end of experiment at 6 h, 
at all-time points (p ≤ 0.01 for 2, 4, and 6 hours, Figure S5B, S5C, S5D).
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